[Form 3] Salarius Pharmaceuticals, Inc. Initial Statement of Beneficial Ownership

Rhea-AI Filing Summary

Salarius Pharmaceuticals, Inc. (SLRX) filed an initial Form 3 reporting the equity holdings of its Chief Business Officer. The filing shows derivative securities rather than direct common stock ownership. The officer holds stock options to buy 5,061 shares of common stock at an exercise price of $4.9369 per share, expiring on 03/31/2032, and options to buy 8,318 shares at $50.2579 per share, expiring on 07/15/2030. The officer also holds Series A Preferred Shares that are convertible into common stock after stockholder approval and satisfaction of specified Nasdaq listing standards, and the preferred shares have no expiration date.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Marschel Peter Klaus

(Last) (First) (Middle)

2450 HOLCOMBE BLVD STE X

(Street)

HOUSTON TX 77021

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
11/12/2025

3. Issuer Name and Ticker or Trading Symbol
Salarius Pharmaceuticals, Inc. [ SLRX ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Business Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series A Preferred Stock	(1)	(1)	Common Stock	50,619	(1)	D
Stock Option (right to buy)	(2)	03/31/2032	Common Stock	5,061	$4.9369	D
Stock Option (right to buy)	(2)	07/15/2030	Common Stock	8,318	$50.2579	D

Explanation of Responses:

1. The Series A Preferred Shares are convertible into 141,734 shares of Common Stock. The Series A Preferred Shares have no expiration date, and convert automatically into shares of Common Stock following stockholder approval and satisfaction of certain Nasdaq listing standards.

2. The Stock Options are exercisable following stockholder approval and satisfaction of certain Nasdaq listing standards.

Remarks:

Exhibit 24, Power of Attorney, is attached.

	/s/Mark Rosenblum, as Attorney-in-Fact	11/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does the Salarius Pharmaceuticals (SLRX) Form 3 filing report?

The Form 3 reports the initial beneficial ownership of Salarius Pharmaceuticals, Inc. (SLRX) securities by its Chief Business Officer, focusing on preferred stock and stock options rather than direct common shares.

What stock options does the Salarius (SLRX) Chief Business Officer hold?

The officer holds stock options to buy 5,061 shares of common stock at $4.9369 per share expiring on 03/31/2032, and options to buy 8,318 shares at $50.2579 per share expiring on 07/15/2030.

How are the Series A Preferred Shares of Salarius (SLRX) treated in this Form 3?

The Form 3 states that the Series A Preferred Shares are convertible into shares of common stock and have no expiration date, with conversion occurring automatically after stockholder approval and satisfaction of certain Nasdaq listing standards.

Are the Salarius (SLRX) stock options immediately exercisable?

No. The Form 3 explains that the stock options become exercisable only after stockholder approval and satisfaction of certain Nasdaq listing standards.

What is the role of the reporting person in Salarius Pharmaceuticals (SLRX)?

The reporting person is an officer of Salarius Pharmaceuticals, Inc., serving as the Chief Business Officer, and is not reported as a director or 10% owner in this filing.

Is there any direct or indirect ownership form disclosed in this SLRX Form 3?

Yes. The filing classifies ownership of the derivative securities as direct (D) beneficial ownership by the Chief Business Officer.